Results 91 to 100 of about 53,685 (285)
Movement Disorders Clinical Practice, EarlyView.Abstract Background New sophisticated deep brain stimulation (DBS) systems enabling steering of current and aiming at improving further motor outcome and decreasing side effects have virtually replaced old omnidirectional systems, despite being more labor‐intensive and expensive.
Marwan Hariz, Patric Blomstedt
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background 22q11.2 deletion syndrome (22q11DS) is a multisystem genetic disorder associated with a significantly increased risk of early‐onset Parkinson's disease (EOPD). Management is challenging because psychiatric and cognitive comorbidities often limit advanced therapies such as deep brain stimulation (DBS). Cases We report 2 patients with
Valle Victor Andrés +10 more
wiley +1 more source
Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
, 2018 Robert A Hauser,1 Aaron Ellenbogen,2 Sarita Khanna,3 Suneel Gupta,3 Nishit B Modi3 1Departments of Neurology, Molecular Pharmacology, and Physiology, University of South Florida, Tampa, FL, USA; 2Quest Research Institute, Bingham Farms, MI, USA; 3Impax ...
Hauser RA +4 more
core
Movement Disorders Clinical Practice, EarlyView.Abstract Background Subthalamic nucleus deep brain stimulation (STN DBS) improves Parkinson's disease (PD)‐related motor symptoms, but how STN DBS impacts various aspects of patient‐perceived health‐related quality of life (HRQoL) is less clear. The Patient‐Reported Outcome Measurement Instrument (PROMIS) and Quality of Life in Neurological Disorders ...
Sarah A. Brinkerhoff +10 more
wiley +1 more source
Frontiers in Neurology, 2019 Parkinson's disease is the second-most common neurodegenerative disorder worldwide. Besides deciphering the mechanisms that underlie the etiology of the disease, it is important to elucidate the factors that influence the efficacy of the treatment ...
Sebastiaan P. van Kessel, Sahar El Aidy
doaj +1 more source
, 2013 Xinxin Yang, Na Wu, Lu Song, Zhenguo Liu Department of Neurology, Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China Background: Levodopa remains the most effective drug for the ...
Yang X, Song L, Liu Z, Wu N
core
Movement Disorders Clinical Practice, EarlyView.Abstract Background Parkinson's disease (PD) is clinically heterogeneous, with variable progression rates that complicate clinical trial design. The data‐driven diffuse malignant (DM), intermediate (IM), and mild‐motor predominant (MMP) subtyping model has prognostic value but lacks disease duration–specific thresholds for prospective use in disease ...
Ahmed Negida +4 more
wiley +1 more source
Neuropsychiatric Disease and Treatment, 2010 Paolo Solla, Antonino Cannas, Francesco Marrosu, Maria Giovanna MarrosuMovement Disorders Center, Institute of Neurology, University of Cagliari, Cagliari, ItalyAbstract: Parkinson disease (PD) is a neurodegenerative disorder characterized by 3 cardinal ...
Paolo Solla +3 more
doaj
Nitrous oxide promotes hyperhomocysteinemia in levodopa treated rats
, 2016 BACKGROUND: This study investigated whether brief exposure to nitrous oxide (N(2)O) exacerbates levodopa-induced hyperhomocysteinemia, and if co-treatment with folate or entacapone could reduce total plasma homocysteine (tHcy) levels.
Schwab, Stefan +4 more
core +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Parkinson's disease (PD) progression is highly heterogeneous, complicating clinical management and prognostication. While machine learning models have been developed using research datasets such as Parkinson's Precision Medicine Initiative (PPMI) and Parkinson's Disease Biomarkers Program (PDBP), their clinical translatability is ...
Xuehua Ye +9 more
wiley +1 more source